CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D) CagriSema vs Tirzepatide: Weight Loss Results in REDEFINE 4 Trial Paramesh Shamanna posted on the topic LinkedIn Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased Evolving Role of Double and Triple Therapy With GLP 1 Receptor Agonists in Obesity and Cardiovascular Disease ScienceDirect Clinical trials of subcutaneous tirzepatide, retatrutide, and Download Scientific Diagram Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine